EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Ameloblastic Carcinoma with Unusual Anterior Mandibular and Pharyngeal Extension in a Patient with Metachronous Renal Cell Carcinoma: A Case Report of a Complex Diagnostic Challenge

Samiya Riaz

Jordan Journal of Dentistry · 2027 · 4 (1)

DOI: 10.14525/jjd.2027.09 ↗
AbstractBibliografische Angaben

Abstract

Ameloblastic carcinoma (AC) is a rare malignant odontogenic tumor characterized by aggressive local behavior and the potential for regional and distant metastasis. Anterior mandibular involvement with pharyngeal extension is exceptionally rare and poses significant diagnostic challenges. We report a 74-year-old man who presented with dysarthria, restricted tongue mobility, submental swelling, and intermittent intraoral bleeding. Imaging revealed an ill-defined radiolucent lesion in the anterior mandible with cortical destruction and extension into the oropharyngeal region. Incisional biopsy confirmed AC. Metastatic workup demonstrated bilateral cervical lymphadenopathy and multiple pulmonary nodules. A history of renal cell carcinoma (RCC), created diagnostic uncertainty regarding the origin of the distant lesions. The lesion was staged as T4bN2cM1 and deemed surgically unresectable. Palliative management was initiated; however, the patient died shortly thereafter. This case highlights a rare co-occurrence of atypical anatomical presentation and multi-malignancy diagnostic complexity, emphasizing the need for refined diagnostic strategies in similar scenarios. Keywords: Ameloblastic carcinoma, Pharyngeal invasion, Renal cell carcinoma, Metachronous malignancy, Mandibular tumor, Odontogenic malignancy

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →